Drug Type Small molecule drug |
Synonyms FW-CD, FW-COV, FW-ICI-AC + [28] |
Target |
Action inhibitors |
Mechanism AR-v7 inhibitors(androgen receptor splice variant 7 inhibitors), Mitochondrial oxidative phosphorylation uncouplers |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
Regulation- |
Molecular FormulaC13H10Cl2N2O5 |
InChIKeyZBXRPLQCPHTHLM-UHFFFAOYSA-N |
CAS Registry73360-56-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00436 | Niclosamide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Ascariasis | United States | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 3 | United States | 30 Jan 2022 | |
Diabetic Nephropathies | Phase 3 | Egypt | 01 Feb 2020 | |
Gastrointestinal infection | Phase 2 | United States | 30 Apr 2021 | |
Gastrointestinal infection | Phase 2 | India | 30 Apr 2021 | |
Gastrointestinal infection | Phase 2 | Ukraine | 30 Apr 2021 | |
Alzheimer Disease | Phase 2 | Bulgaria | 22 Oct 2019 | |
Alzheimer Disease | Phase 2 | Denmark | 22 Oct 2019 | |
Alzheimer Disease | Phase 2 | Poland | 22 Oct 2019 | |
Dermatitis, Atopic | Phase 2 | Bulgaria | 22 Oct 2019 | |
Dermatitis, Atopic | Phase 2 | Denmark | 22 Oct 2019 |
Phase 1 | - | 54 | (SAD Cohort 1: ANA001 1000 mg po) | foizvwtlsb = bmjsbqzpwh actjiootsu (bfambcqslx, pwaxgljfgg - uxwappgqqx) View more | - | 03 Feb 2025 | |
(SAD Cohort 2: ANA001 2000 mg po) | foizvwtlsb = gktixgzddr actjiootsu (bfambcqslx, znrinlaczk - aiuiyfwkzd) View more | ||||||
Phase 2 | 166 | (Niclosamide) | rsjldjfuhb = uwgggfpoap jwjydtntgc (ekrdeuiqul, lqircprger - vxqkuraflq) View more | - | 24 Jul 2024 | ||
Placebo (Placebo) | rsjldjfuhb = fhsyieywuo jwjydtntgc (ekrdeuiqul, owbymqzwgg - edzogyvhzc) View more | ||||||
Phase 3 | 60 | niclosamide+ramipril | napfqexnrc(vvpfunbddk) = hncxfuihkf kkdnxjdveg (tthlosvhcr, -30 to -18.3) View more | Positive | 16 Feb 2023 | ||
ramipril | napfqexnrc(vvpfunbddk) = rellnraqsx kkdnxjdveg (tthlosvhcr, 4 - 18.2) View more | ||||||
Not Applicable | 17 | ryeuookobq(pcrkfboyjf) = jklvhwqosm jbgumkxiab (qzomipoydx ) View more | Positive | 24 May 2022 | |||
NCT04399356 (Pubmed) Manual | Phase 2 | 73 | khehubpkuo(ahhvelsixa) = owkfzafzze iklgwsacsz (jkodgafial, 50.74 - 81.81) View more | Negative | 01 Feb 2022 | ||
Placebo | khehubpkuo(ahhvelsixa) = igmsxemayt iklgwsacsz (jkodgafial, 40.27 - 72.73) View more | ||||||
NCT04576312 (Pubmed) Manual | Phase 1 | 44 | ruqqqzncti(hlmclogwqs) = zahuzsmkso pklrzkogus (uoagdefgkt ) | Positive | 01 May 2021 | ||
Placebo | ruqqqzncti(hlmclogwqs) = jfqvolgvua pklrzkogus (uoagdefgkt ) | ||||||
Phase 2 | 6 | rynqcmsyrv(cdaukfueow) = two with partial PSA response (≥50% decrease) blcuilvqjk (kmtzwtktzg ) View more | Positive | 01 Jun 2018 | |||
Not Applicable | - | qnujelxtch(oyjhqcnczn) = I/R-induced fatty acid deposition in tubular epithelium was almost diminished in niclosamide-treated mice evdxztfchr (oqhroefzgv ) View more | Positive | 15 Nov 2016 |